[Form 4] Bio-Rad Laboratories, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Eva Anette Engelhardt, EVP and President, CDG at Bio-Rad Laboratories (BIO), reported changes in her holdings in two filings dated 09/05/2025–09/06/2025. On 09/05/2025 4,110 restricted stock units (RSUs) vested, each representing one share, and were reported as acquired. On 09/06/2025 an additional 1,152 RSUs were recorded as acquired (noted as a deemed execution/plan transaction), and separately 413 shares were disposed at a price of $295.43 on 09/06/2025. The filing shows resulting beneficial ownership counts after these transactions and is signed by Ms. Engelhardt on 09/09/2025. The RSUs vest over four years at 25% per year per the filing.

Positive

• 4,110 RSUs vested, increasing the reporting person's direct alignment with shareholders
• Additional 1,152 RSUs recorded, indicating continued equity compensation consistent with retention incentives
• Vesting schedule disclosed (25% per year over four years) provides transparency on future dilution timing

Negative

• 413 shares sold at $295.43, reducing the reporting person’s share count
• Some transactions noted as Code M (planned transactions) which may limit visibility into timing rationale

Insights

Corporate Governance Expert

TL;DR: Routine executive compensation vesting with a small open-market sale; no new material transactions disclosed.

This Form 4 documents scheduled vesting of equity awards and a contemporaneous sale. The 4,110 RSUs vesting and the additional 1,152 RSUs recorded under a Rule 10b5-1 or similar mechanism increase the reporting officer's direct stake. The 413-share sale at $295.43 appears modest relative to typical executive holdings and is consistent with diversification or tax-withholding needs rather than a material change in control or strategy. The filing includes the vesting schedule (25% per year over four years), which signals standard time-based alignment with shareholder interests.

Compensation & Equity Plan Specialist

TL;DR: Transactions reflect standard equity compensation mechanics—vesting and a small disposition—without unusual terms.

The report clarifies that each RSU converts to one Class A share and vests ratably over four years. The acquisition entries show $0 consideration for vested RSUs, as expected, and the separate sale of 413 shares at $295.43 likely reflects either tax-withholding or selective monetization. Nothing in the filing indicates acceleration, re-pricing, or special one-off awards; this aligns with routine compensation governance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ENGELHARDT EVA ANETTE

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, President, CDG

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/06/2025		M		1,152(1)	A	$0	1,309	D
Bio-Rad A Common Stock	09/06/2025		F		413	D	$295.43	896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	09/05/2025		A		4,110		(3)	(3)	Bio-Rad A Common Stock	4,110	$0	4,110	D
Restricted Stock Units	$0(2)	09/06/2025		M			1,152	(3)	(3)	Bio-Rad A Common Stock	1,152	$0	3,456	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Eva Anette Engelhardt	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What RSU transactions did Eva Anette Engelhardt report on Form 4 for BIO?

The filing reports 4,110 RSUs vested on 09/05/2025 and an additional 1,152 RSUs recorded on 09/06/2025.

Did the Form 4 show any share sales by the insider for BIO?

Yes; the report shows a disposition of 413 shares sold on 09/06/2025 at $295.43 per share.

How do the RSUs convert into Bio-Rad shares according to the filing?

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock upon vesting.

What is the vesting schedule for the RSUs reported on the Form 4?

The RSUs vest over four years at 25% per year on each anniversary of the grant.

When was the Form 4 signed by the reporting person?

The Form 4 is signed by Eva Anette Engelhardt on 09/09/2025.

What positions does the reporting person hold at Bio-Rad (BIO)?

The filer is listed as EVP, President, CDG and is an officer of Bio-Rad Laboratories.